{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:40:33Z","timestamp":1776400833136,"version":"3.51.2"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ejim.2021.05.020","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T05:03:40Z","timestamp":1623387820000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study"],"prefix":"10.1016","volume":"91","author":[{"given":"Sake J.","family":"van der Wall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Teutsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskars","family":"Kalejs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Lyrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-4382","authenticated-orcid":false,"given":"Christian","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9449-9225","authenticated-orcid":false,"given":"Sergio J.","family":"Dubner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-8612","authenticated-orcid":false,"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8318-5471","authenticated-orcid":false,"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Sheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-1705","authenticated-orcid":false,"given":"Kenneth J.","family":"Rothman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Zint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongmei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1423-5348","authenticated-orcid":false,"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2021.05.020_bib0001","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","author":"Hindricks","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2021.05.020_bib0002","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2021.05.020_bib0003","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jacc.2013.04.089","article-title":"Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study","volume":"62","author":"Airaksinen","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2021.05.020_bib0004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/europace\/euu189","article-title":"Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy","volume":"17","author":"Hansen","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ejim.2021.05.020_bib0005","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jacc.2018.07.083","article-title":"Direct oral anticoagulants halve thromboembolic events after cardioversion of AF compared with warfarin","volume":"72","author":"Kotecha","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2021.05.020_bib0006","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"Calkins","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2021.05.020_bib0007","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2021.05.020_bib0008","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1093\/eurheartj\/ehz190","article-title":"Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial","volume":"40","author":"Hohnloser","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2021.05.020_bib0009","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1093\/eurheartj\/ehy176","article-title":"Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation","volume":"39","author":"Kirchhof","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2021.05.020_bib0010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jacc.2016.11.024","article-title":"2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology clinical expert Consensus Document Task Force","volume":"69","author":"Doherty","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2021.05.020_bib0011","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2021.05.020_bib0012","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1093\/eurheartj\/ehy413","article-title":"Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2)","volume":"39","author":"Birnie","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2021.05.020_bib0013","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines.","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2021.05.020_bib0014","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa624","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2021.05.020_bib0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2021.05.020_bib0016","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1160\/TH15-01-0061","article-title":"Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease The X-PLORER trial","volume":"114","author":"Vranckx","year":"2015","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.ejim.2021.05.020_bib0017","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4244\/EIJV8I9A162","article-title":"A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients","volume":"8","author":"Vranckx","year":"2013","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ejim.2021.05.020_bib0018","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ahj.2013.12.006","article-title":"Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation","volume":"167","author":"Huisman","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2021.05.020_bib0019","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.amjmed.2015.07.013","article-title":"Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, phase II","volume":"128","author":"Huisman","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2021.05.020_bib0020","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2021.05.020_bib0021","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2021.05.020_bib0022","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2021.05.020_bib0023","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2021.05.020_bib0024","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.amjcard.2017.11.015","article-title":"Safety of uninterrupted periprocedural edoxaban versus phenprocoumon for patients who underwent left atrial catheter ablation procedures","volume":"121","author":"Kottmaier","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2021.05.020_bib0025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10840-016-0195-5","article-title":"Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation","volume":"48","author":"Ukaigwe","year":"2017","journal-title":"J Interv Card Electrophysiol"},{"key":"10.1016\/j.ejim.2021.05.020_bib0026","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.amjcard.2012.12.046","article-title":"Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices","volume":"111","author":"Rowley","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2021.05.020_bib0027","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/jce.12214","article-title":"Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin","volume":"24","author":"Jennings","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ejim.2021.05.020_bib0028","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2021.05.020_bib0029","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521001710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521001710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:35:05Z","timestamp":1760607305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620521001710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":29,"alternative-id":["S0953620521001710"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.05.020","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}